Baird Maintains Outperform on TransMedics Gr, Lowers Price Target to $150
Portfolio Pulse from Benzinga Newsdesk
Baird analyst Joe Vruwink maintains an Outperform rating on TransMedics Group (NASDAQ:TMDX) but lowers the price target from $200 to $150.
October 29, 2024 | 12:01 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Baird analyst Joe Vruwink continues to rate TransMedics Group as Outperform, but has reduced the price target from $200 to $150, indicating a more conservative outlook.
The reduction in price target from $200 to $150 suggests a more cautious outlook on the stock's potential, which could lead to a short-term negative impact on the stock price despite the maintained Outperform rating.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100